Drug intelligence / Profile preview

APMV-4

Development stage: Unknown
Lead developer: Mount Sinai Health System
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

**APMV-4** is a naturally occurring avian paramyxovirus serotype 4, identified as a novel oncolytic virus (OV) with superior antitumor activity compared to Newcastle disease virus (NDV/APMV-1) strains like LaSota in preclinical models. It selectively replicates in and lyses cancer cells due to their defective antiviral responses, while sparing normal cells, and is not a human pathogen with no pre-existing immunity in humans. Intratumoral administration in syngeneic mouse models of B16F10 melanoma and CT26.WT colon carcinoma demonstrated potent tumor growth inhibition, complete remissions (up to 100% when combined with VEGF-C expression), extended survival, and long-term protection against tumor rechallenge, correlated with enhanced T-cell and NK-cell infiltration and lymphangiogenesis. Recombinant versions (rAPMV-4) have been engineered via reverse genetics to express transgenes like GFP, enabling further optimization for therapeutic delivery.[1][2][5][7]

Other names: Avian paramyxovirus 4Duck/Hong Kong/D3/1975

Beyond the preview

Go deeper on APMV-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APMV-4.

Explore the full profile